Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma-the randomized phase 2 INTEGA trial (AIO STO 0217)

Tintelnot, J; Goekkurt, E; Binder, M; Thuss-Patience, P; Lorenzen, S; Knorrenschild, JR; Kretzschmar, A; Ettrich, T; Lindig, U; Jacobasch, L; Pink, D; Al-Batran, SE; Hinke, A; Hegewisch-Becker, S; Nilsson, S; Bokemeyer, C; Stein, A

Stein, A (corresponding author), Univ Med Ctr Hamburg Eppendorf, Dept Internal Med 2, Hubertus Wald Tumorzentrum UCCH, Oncol Ctr, Martinistr 52, D-20246 Hamburg, Germany.; Stein, A (corresponding author), Hematol Oncol Practice Hamburg HOPE, Hamburg, Germany.

BMC CANCER, 2020; 20 (1):

Abstract

Background Esophagogastric adenocarcinoma (EGA) currently represents a main cause of cancer related death. Despite an intensified treatment for locall......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索